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Optimal Population of FoxP3+ T Cells in Tumors Requires
an Antigen Priming-Dependent Trafficking Receptor
Switch
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Abstract
FoxP3+ T cells populate tumors and regulate anti-tumor immunity. The requirement for optimal population of FoxP3+
regulatory T cells in tumors remains unclear. We investigated the migration requirement and stability of tumor-associated
FoxP3+ T cells. We found that only memory, but not naı̈ve, FoxP3+ T cells are highly enriched in tumors. Almost all of the
tumor-infiltrating FoxP3+ T cells express Helios, an antigen associated either with thymus-generated FoxP3+ T cells or
activated T cells in the periphery. The tumor-infiltrating FoxP3+ T cells largely lack CD62L and CCR7, two trafficking receptors
required for T cell migration into secondary lymphoid tissues. Instead, the tumor infiltrating FoxP3+ T cells highly express
memory/tumor-associated CCR8 and CXCR4. Antigen priming is required for induction of this trafficking receptor
phenotype in FoxP3+ T cells and only antigen primed, but not antigen-inexperienced naive, FoxP3+ T cells can efficiently
migrate into tumors. While the migration of FoxP3+ T cells into tumors was a readily detectable event, generation of
induced FoxP3+ T cells within tumors was unexpectedly inefficient. Genetic marking of current and ex-FoxP3+ T cells
revealed that tumor-infiltrating FoxP3+ T cells are highly stable and do not readily convert back to FoxP32 T cells. Taken
together, our results indicate that population of tumors with thymus-generated FoxP3+ T cells requires an antigen primingdependent trafficking receptor switch in lymphoid tissues.
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cells positively correlated with the patient survival rate [19–22].
For some tumors, no correlation between tumor-infiltrating
FoxP3+ T cells and the patient survival rate was observed. Thus,
the roles of tumor-associated FoxP3+ T cells appear to be
complex.
The requirement for population of FoxP3+ T cells in tumors is
incompletely understood. To account for the enrichment of Tregs
in tumors, several explanations have been provided. For example,
migration of Tregs into tumors in response to certain chemokines
has been proposed [16,23,24]. Induction of FoxP3+ Tregs in
tumors from conventional T cells in response to dendritic cells has
been proposed as well [25–28]. Another explanation comes from
the evidence that Tregs undergo proliferation with a low rate of
apoptosis in tumors [29,30]. Despite these explanations, many
questions remain unanswered. 1) Are tumor-infiltrating FoxP3+ T
cells the result of conversion from naı̈ve FoxP32 T cells in tumors
or migration of pre-existing FoxP3+ T cells? 2) What is the
requirement for FoxP3+ T cells to migrate into tumors? 3) Are the
FoxP3+ T cells in tumors stable or do they become conventional
FoxP32 T cells in tumors? To provide more insights into the
biology of FoxP3+ T cells in tumors, we studied the phenotype,
induction, stability, and migration behavior of FoxP3+ T cells in
tumors. Our results indicate that the antigen priming-dependent
switch of trafficking receptor phenotype is important for
infiltration of FoxP3+ T cells in tumors.

Introduction
FoxP3+ regulatory T cells (Tregs) play critical roles in inducing
tolerance in the body [1–6]. Naı̈ve FoxP3+ T cells are generated in
the thymus and programmed to migrate mainly to secondary
lymphoid tissues [7]. Memory FoxP3+ T cells are generated from
the thymus-generated naı̈ve FoxP3+ T cells or naı̈ve FoxP32 T
cells in secondary lymphoid tissues following antigen priming.
Memory FoxP3+ T cells are heterogeneous in trafficking
potentials. Some memory FoxP3+ T cells migrate into various
non-lymphoid tissues, whereas others preferentially migrate into
secondary lymphoid tissues [7].
FoxP3+ T cells can suppress anti-tumor immunity, and
depletion of these cells using anti-CD25 antibody or cyclophosphamide was effective in eradicating some transplantable tumors
in animals [8–12]. Depletion of Tregs led also to slower and
inefficient induction of tumors by carcinogens such as methylcholanthrene [13]. FoxP3+ T cells suppress the anti-tumor
effector function of both CD4+ Th1 cells and cytolytic CD8+ T
cells [14,15]. For some tumors, inflammation can promote
tumorigenesis. For these types of tumors, FoxP3+ T cells could
affect tumorigenesis by decreasing inflammation. FoxP3+ T cells
are frequently found also in human tumors, and their presence
within some types of tumors predicts reduced patient survival
[16–18]. In other tumor types, however, the number of FoxP3+ T
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that migrated into various tissue sites were identified with flow
cytometry using antibodies to DO11.10 TCR (KJ1-26) and FoxP3.
Similar homing experiments were performed with wild type and
CCR7 (2/2) CD4+ cells isolated from spleen and lymph nodes
(inguinal, auxiliary, and brachial) and antigen-primed in vitro in
complete RPMI 1640 medium (10% FBS) supplemented with
concanavalin A (0.5 mg/ml, Sigma) and hIL-2 for 5 days. Wild
type cells (16107 cells/mouse; labeled with tetramethylrhodamine
isothiocyanate (TRITC)) and CCR7 (2/2) cells (16107 cells/
mouse; labeled with CFDA-SE) were co-injected i.v. into C57BL/
6 mice each bearing a tumor of ,10 mm diameter. The host mice
were sacrificed 36 h later, and indicated organs were harvested.
The numbers of injected CFDA-SE+ or TRITC+ FoxP3+ cells
migrated into each organ were determined with flow cytometry.
Absolute numbers of T cells that migrated into various organs
were determined as described before [7]. We also normalized the
absolute number of the T cells present in each organ with that of
the injected cells to obtain a parameter termed ‘homing index.’

Methods
Mice, cell isolation, and tumor cell lines
BALB/c mice and C57BL/6 mice (6 to 8 weeks old) were
purchased from Harlan (Indianapolis, IN). FoxP3-GFP-Cre6Rosa-tdTomato mice [31], CCR7 (2/2) mice, and B6.Cg-Foxp3sf/
J mice were purchased from the Jackson laboratory. Rat insulin
promoter (RIP)-membrane-bound ovalbumin (mOVA)6DO11.10
Treg mice in Rag2 (2/2) background were described before [7].
DO11.10 TCR Rag2 (2/2) transgenic mice were purchased
from Taconic Farms. All animals were used according to the
protocols (04-048 and 02-067) approved by the Purdue Animal
Care and Use Committee. A20, B16, CT26 and 4T1 tumor cell
lines were purchased from American Type Culture Collection
(ATCC, Rockville, MD, USA). For ovalbumin (OVA) expressing
tumor cells, A20 cells, and 4T1 cells were transfected with
linearized pAC-neo-OVA [32] or pCDNA3.1-hygromycin-OVA
by using Gene Pulser (at 250 V, 975 mF; Bio-Rad, Hercules, CA,
USA). Stably transfected cells were selected with G418 (1 mg/ml
for pAC-neo-OVA) or hygromycin B (0.4 mg/ml for pCDNA3.1Hygromycin) for 2–3 weeks. CD4+ T cells (purity .95%) were
isolated as described before [33].

Induction of FoxP3+ T cells in lymph nodes versus tumors
Splenocytes isolated from DO11.10 Rag2 (2/2) mice (26106
cells/mouse; containing naı̈ve FoxP32 but not FoxP3+ CD4+ T
cells) were injected i.v. into Rag2 (2/2) BALB/c mice, and then
the mice were implanted with A20-OVA tumor cells 15 hours
later. Mice were sacrificed 2 weeks later when tumor size was
,10 mm, and conversion rate of naı̈ve FoxP32 CD4+ T cells into
FoxP3+ T cells (represented by % FoxP3+ cells of KJ1.26+ CD4+ T
cells) was determined in various organs and tumors.

Tumor formation in mice
A20 (or A20-OVA), CT26, and 4T1 (or 4T1-OVA) cells were
cultured in RPMI 1640 (Invitrogen) supplemented with 10% fetal
bovine serum (FBS). B16 cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% FBS.
A20 cells (26106 cells/mouse) or CT26 cells (36105 cells/mouse)
were injected s.c. in the right flank of BALB/c mice. B16 cells
(26105 cells/mouse) were similarly injected into C57BL/6 mice.
4T1 cells (16104 cells/mouse) were implanted s.c. in the
mammary glands of female BALB/c mice. Tumor size was
measured daily with a digital caliper. Most experiments were
performed when the tumor diameter was ,10 mm.

Comparison of the population of wild type and
CCR7 (2/2) FoxP3+ cells in tumors
Wild type CD45.1+ CD4+ T cells and CCR7 (2/2) CD45.2+
CD4+ T cells (containing ,26106 FoxP3+ cells/mouse) were
intraperitoneally transferred into scurfy mice deficient with FoxP3
expression on day 2 following birth. At 5 weeks of age, B16 tumor
cells were implanted into the flank of scurfy mice that were
previously co-injected with wild type and CCR7 (2/2) CD4+ T
cells. When the tumor size was ,10 mm, the indicated organs
were harvested, and the frequency and phenotype of FoxP3+ cells
were determined with flow cytometry. In separate experiments,
wild type and CCR7 (2/2) CD4+ T cells were separately injected
into scurfy mice for assessment of their population in tumors in a
non-competitive setting.

Assessment of expression of trafficking receptors and
Helios
Single-cell suspensions of tumor, draining inguinal lymph node
(D-LN), or mixed peripheral lymph nodes (inguinal, auxiliary, and
brachial) were prepared by grinding tissues through an iron mesh.
The cells were stained with an antibody to CCR7 (clone 4B12;
eBioscience) or CXCR4, (2B11; BD Biosciences) or rat control
IgG2a antibody (clone RTK2758; BioLegend) for 30 min on ice.
The cells were additionally stained with biotinylated anti-rat
IgG2a (RG7/1.30; BD Biosciences) for 30 min, followed by
staining with allophycocyanin-streptavidin (BD Biosciences) and
antibodies to CD62L (clone MEL-14; BioLegend), CD44 (IM7;
BioLegend), and CD4 (clone RM4-5; BioLegend). The cells were
further stained with antibodies to FoxP3 (FJK-16s; eBioscience)
and/or Helios (22F6; BioLegend) according to the manufacturer’s
protocol. CCR8 expression was detected with a home-made
mCCL1-hFc protein, biotin-anti-hIgG (Vector Lab) and allophycocyanin-streptavidin.

Chemotaxis
Chemotaxis was assessed using Transwell chambers (5 mm
pores; Corning). Total lymph node cells and B220+ A20 tumor
cell-depleted tumor mononuclear cells were used for the
chemotaxis assay. 0.5 million cells were added to the top chambers
and chemokines were added at optimal concentrations (1000 ng/
ml of CCL1; 500 ng/ml of CCL19; 1000 ng/ml of CCL21;
250 ng/ml of CXCL12; all are mouse chemokines purchased
from R&D systems or PeproTech) in the lower chambers. Cells
were allowed to migrate for 3 h. The cells migrated to the lower
chambers were stained with antibodies to CD4 and FoxP3 and
analyzed by flow cytometry as described previously [34]. The
numbers of migrated cells were normalized for the numbers of the
same cell types in input cells to obtain the index ‘‘% migration.’’

Homing experiments
For homing experiments, splenocytes and lymph node cells
isolated from RIP-mOVA6DO11.10 Treg-enriched mice were
prepared and cultured in the presence of hIL-2 (25 U/ml;
PeproTech, Rocky Hill, NJ) and the peptide OVA323–339 (1 mg/
ml) for 5 days. Activated KJ1-26+ FoxP3+ T cells (,16107 cells/
mouse) were labeled with carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) and injected via a tail vein of mice when
tumors reach a diameter of ,10 mm. The KJ1-26+ FoxP3+ cells
PLoS ONE | www.plosone.org
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tumors reach ,10 mm in diameter. Frozen sections (8 mm) of A20
tumors were stained with antibodies to CD4, FoxP3 and Helios for
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Figure 1. Tumor-infiltrating FoxP3+ T cells express the Helios antigen. Mice harboring one of the four types of tumors (A20 B cell lymphoma,
CT26 colon cancer, 4T1 breast cancer, and B16 melanoma) were examined for expression of Helios by FoxP3+ T cells. (A) Helios expression by FoxP3+
T cells in tumors and various secondary lymphoid tissues such as the draining lymph node (D-LN), other peripheral lymph nodes (PLN), and
mesenteric lymph node (MLN). (B) Frequencies of Helios-negative FoxP3+ T cells in tumors and secondary lymphoid tissues. (C) Detection of Helios+
FoxP3+ T cells in tumors by confocal microscopy. Arrows indicate T cells that co-express FoxP3 and Helios in tumors. Representative and combined
(n = 4) data are shown. ‘‘*’’ indicates significant differences from tumors.
doi:10.1371/journal.pone.0030793.g001
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frequencies of Helios-expressing FoxP3+ T cells were highest in
tumors among the tissues examined, which included the draining
lymph node (D-LN), non-draining peripheral lymph nodes (PLN),
and mesenteric lymph nodes (MLN) (Fig. 1A and B). We
examined four different tumor types (A20 B cell lymphoma,
CT26 colon cancer, 4T1 breast cancer, and B16 melanoma), and
the results were comparable with all of the tumor types.
Furthermore, we were able to observe the presence of these
Helios+ FoxP3+ T cells infiltrating A20 tumors using an
immunohistochemistry technique (Fig. 1C).

40 minutes as described previously [33]. The images were
acquired with a Leica SP5 II confocal microscope housed in the
Super-resolution Imaging Lab (Purdue Veterinary Medicine).

Statistical analyses
Averages with SEM are shown in most of the figures. Student’s
paired t test (2-tailed) or Mann-Whitey test was used to determine
the significance of differences between two groups. p values,or = 0.05 were considered significant.

Results
Tumors are enriched with Helios FoxP3 T cells

Induced FoxP3+ T cells are found more frequently in
tumor-draining lymph nodes than in tumors

Helios is known to be preferentially expressed by thymusderived FoxP3+ T cells and activated T cells in proliferation
[35,36]. To gain insights into the phenotype of FoxP3+ T cells
populating tumors, we examined the expression of Helios in
FoxP3+ T cells infiltrating tumors formed in mice. Interestingly,

A potential way to increase the number of tumor-infiltrating
FoxP3+ T cells is through efficient conversion of FoxP32 T cells into
FoxP3+ T cells in tumors. We examined this possibility utilizing
DO11.10 Rag2 (2/2) T cells, which express TCR specific for an
OVA epitope. Almost all T cells in DO11.10 Rag2 (2/2) mice are

+

+

Figure 2. Induction of FoxP3+ regulatory T cells in tumors is inefficient, and most tumor-infiltrating FoxP3+ T cells have the memory
phenotype. (A) Splenocytes of DO11.10 Rag22/2 mice (containing naı̈ve FoxP32 CD4+ T cells but not FoxP3+ T cells) were injected i.v. into BALB/c
mice, and A20 tumor cells expressing OVA were implanted 15 hours later. Mice were sacrificed 2 weeks later, and the conversion rate of naı̈ve FoxP32
CD4+ T cells into FoxP3+ T cells (represented by % FoxP3+ of KJ-1.26+ CD4+ T cells) was determined in various organs and tumors. (B) Memory FoxP3+
T cells are enriched in tumors. Expression of CD44 and CD62L by FoxP3+ T cells in tumors and peripheral lymph nodes were compared.
Representative and combined data obtained from 3 (A) or 5–8 different experiments (B) are shown. ‘‘*’’ indicates significant differences between the
tumor and indicated organs (A) or PLN (B).
doi:10.1371/journal.pone.0030793.g002
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FoxP32 T cells because thymus-derived FoxP3+ T cells are not
made in these mice due to Rag2 deficiency. We injected DO11.10
Rag2 (2/2) FoxP32 T cells into A20-OVA tumor-bearing mice
and determined the frequency of FoxP3+ T cells converted from
FoxP32 T cells 2 weeks after transfer of the cells. We found that
peripheral lymph nodes and the blood were the compartments that
had the highest frequencies (,35%) of OVA-specific FoxP3+ T cells
(Fig. 2A). In contrast, the frequency in tumors was only ,10%,
which is the basal level similar to that of other organs such as MLN,
spleen and marrow. The data suggest that the conversion is more
active in peripheral lymph nodes than in tumors.

They are identified as CD442CD62L+ cells. Upon antigen
priming in secondary lymphoid tissues such as draining lymph
nodes, thymus-derived FoxP3+ T cells lose CD62L but up-regulate
CD44. Interestingly, the majority of FoxP3+ T cells in tumors
expressed CD44 but not CD62L, which is a memory T cell
phenotype (Fig. 2B). In contrast, the majority of FoxP3+ T cells in
lymph nodes had the naı̈ve cell phenotype.

Tumor-infiltrating FoxP3+ T cells lack secondary
lymphoid tissue homing receptors
All naı̈ve type FoxP3+ T cells highly express CD62L and CCR7,
two major trafficking receptors for migration into peripheral
lymph nodes [5]. Memory type FoxP3+ T cells are divided into
CCR7+ secondary lymphoid tissue-homing cells and CCR72 nonlymphoid tissue-homing cells. To determine which memory cell
type is populating tumors, we examined expression of CCR7 by

Tumor-infiltrating FoxP3+ T cells are largely composed of
memory type cells
FoxP3+ T cells, generated in the thymus, are similar to
conventional naı̈ve CD4+ T cells in trafficking potential [37].

Figure 3. Tumor-infiltrating Helios+ FoxP3+ T cells are down-regulated for CD62L and CCR7. (A) Expression of CCR7 and CD62L by Helios+
FoxP3+ T cells in indicated organs and tumors (A20). (B) Expression of CCR7 and CD62L by Helios+ FoxP3+ T cells in indicated tumors and organs.
Representative and combined data obtained from 4–6 different experiments are shown. ‘‘*’’ indicates significant differences from the tumor.
doi:10.1371/journal.pone.0030793.g003
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the FoxP3+ T cells in tumors (Fig. 3A). Helios+ FoxP3+ T cells in
A20 B cell lymphoma tumors largely lacked CCR7 expression. At
the same time, these FoxP3+ T cells in tumors lacked CD62L
expression. In contrast, draining peripheral lymph nodes and
other lymphoid tissues had many FoxP3+ T cells expressing CCR7
and CD62L. The FoxP3+ T cells in other tumor types were
similarly deficient in expression of CCR7 and CD62L (Fig. 3B).

expression phenotype was examined, the majority of FoxP3+ T
cells that migrated into tumors were CD62L-negative (Fig. 4B).
This phenotype was similar to those migrated into the bone
marrow or circulating in blood. In contrast, those migrated into
the peripheral lymph node (PLN) and the mesenteric lymph node
(MLN) were CD62L-positive. Thus, these results indicate that
CD62L-negative memory type FoxP3+ T cells actively migrate
into tumors.

Active migration of memory, but not naı̈ve, FoxP3+ T
cells into tumors

Antigen priming promotes both down-regulation of
CCR7 and migration of FoxP3+ T cells into tumors

Direct migration of preformed FoxP3+ T cells into tumors is a
potential mechanism for the enrichment of FoxP3+ T cells in
tumors. We examined this possibility by performing a short term
homing assay. FoxP3+ T cells were injected into A20 tumorbearing mice and their migration into tumors within the 36 h time
period was examined (Fig. 4A). On average, ,10% of injected
FoxP3+ T cells migrated into tumors among the organs examined,
and this migration rate for tumors was comparable to other organs
such as peripheral and mesenteric lymph nodes and significantly
better than that of marrow (not shown). When the CD62L

The data presented so far implicate the loss of CCR7 and
CD62L and memory phenotype in infiltration of tumors with
FoxP3+ T cells. Because this phenotype is induced following
antigen priming, we compared the expression of CCR7 and the
migration ability of antigen primed and non-primed FoxP3+ T
cells. We activated OVA-specific FoxP3+ T cells isolated from
RIP-mOVA6DO11.10 Rag2 (2/2) mice with the OVA323–339
peptide and irradiated splenocytes as antigen presenting cells for 7
days in vitro. We comparatively examined the CCR7 expression

Figure 4. Memory type FoxP3+ regulatory T cells are more efficient than naı̈ve type FoxP3+ T cells in migration into tumors. Pooled
mononuclear cells including FoxP3+ T cells prepared from spleen, MLN and PLN were injected into BALB/c mice bearing A20 tumors, and the mice
were sacrificed 36 hours later. (A) Detection of the migration of FoxP3+ cells into tumors. (B) Frequencies of naı̈ve versus memory FoxP3+ T cells that
migrated into various organs and tumors. Naı̈ve FoxP3+ T cells are defined as CD62L+ (CD442) cells, and memory FoxP3+ T cells are defined as
CD62L2 (CD44+/2) cells. Representative and combined data obtained from 4 different experiments are shown. ‘‘*’’ indicates significant differences
between frequencies of naı̈ve and memory FoxP3+ T cells.
doi:10.1371/journal.pone.0030793.g004
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function of CCR7 is to guide T cells into secondary lymphoid
tissues for antigen priming. Without the migration and antigen
priming in secondary lymphoid tissues, FoxP3+ T cells may not
populate the tumors well. To determine the role of CCR7 in
population of lymphoid tissues and then eventually into tumors,
we compared the abilities of CCR7 (+/+) and CCR7 (2/2)
FoxP3+ T cells separately transferred into tumor-bearing scurfy
mice, which lack FoxP3+ T cells and develop systemic inflammation (Fig. 6A). CCR7 (2/2) FoxP3+ T cells were less efficient in
population of lymph nodes and tumors. We also co-transferred
CCR7 (+/+) and CCR7 (2/2) FoxP3+ T cells for competitive
population in tumor-bearing scurfy mice (Fig. 6B). Most FoxP3+ T
cells populating both lymphoid tissues and tumors were CCR7 (+/+),
but not CCR7 (2/2), cells. Importantly, the wild type FoxP3+ T
cells that migrated into tumors in scurfy mice were largely
deficient in expression of CCR7 and CD62L (Fig. 6C). These
results together with other data indicate that CCR7 is important
for migration of FoxP3+ T cells into lymph nodes for antigen
priming of FoxP3+ T cells. Antigen primed FoxP3+ T cells lose
CCR7 which is important for migration and therefore population
of FoxP3+ T cells in tumors.

and migration ability of the activated and freshly isolated
lymphoid tissue FoxP3+ T cells. Antigen-primed FoxP3+ T cells
were largely negative in expression of CCR7 (Fig. 5A) and were
greatly enhanced in their ability to migrate into 4T1-OVA tumors
compared to the freshly isolated lymphoid tissue FoxP3+ T cells
(Fig. 5B).
The enhanced migration of antigen-primed FoxP3+ T cells
could be due to acquisition of memory cell-associated nonlymphoid tissue homing receptors and/or loss of CCR7. To
determine if loss of CCR7 plays any role in the migration, we
utilized CCR7 (2/2) mice. We compared the migration of
antigen primed CCR7 (2/2) and wild type CCR7 (+/+) cells into
tumors. CCR7 (2/2) FoxP3+ T cells were not able to efficiently
migrate into PLN and MLN but more efficiently migrated into
tumors, compared to CCR7 (+/+) FoxP3+ T cells (Fig. 5C). The
numbers of CCR7 (2/2) FoxP3+ T cells were greater than the
numbers of their CCR7 (+/+) counterparts in the blood,
suggesting that the cells that could not migrate into secondary
lymphoid tissues were instead circulating in the blood.
The data indicate the presence of a potential negative role for
CCR7 in population of FoxP3+ T cells in tumors. The established

Figure 5. FoxP3+ cells lose CCR7 expression upon antigen priming, and only antigen primed CCR7low cells can efficiently migrate
into tumors. (A) Loss of CCR7 on FoxP3+ T cells following antigen priming. OVA-specific FoxP3+ T cells isolated from RIP-mOVA6DO11.10 Rag2 (2/2)
mice were cultured in the presence of the OVA323–339 peptide and irradiated splenocytes as antigen presenting cells for 7 days, and CCR7 expression by
FoxP3+ T cells was examined. (B) Comparison of the homing ability of antigen primed versus naı̈ve FoxP3+ T cells. Fresh and antigen-primed FoxP3+ T
cells were co-injected i.v. into 4T1-OVA tumor-bearing mice and the relative migration of the two FoxP3+ T cell populations into tumors and other organs
were determined 36 h following the injection. (C) Comparison of antigen primed wild type and CCR7 (2/2) FoxP3+ T cells into tumors. CD4+ T cells,
isolated from wild type and CCR72/2 mice were antigen primed in vitro for 5 days and injected into B16-tumor bearing mice. The relative migration of
the two FoxP3+ T cell populations into tumors and other organs were determined 36 h following the injection. Representative and combined data
obtained from 4–5 different experiments are shown. ‘‘*’’ indicates significant differences between the tumor and indicated organs (B) or between WT
and CCR7 (2/2) FoxP3+ T cells (C).
doi:10.1371/journal.pone.0030793.g005
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Figure 6. Naı̈ve FoxP3+ T cells that cannot migrate first to lymphoid tissues fail to populate tumors. (A) Population of wild type versus
CCR7 (2/2) FoxP3+ T cells in tumors. Wild type and CCR7 (2/2) CD4+ T cells, which were freshly isolated from lymphoid tissues, were separately
transferred into scurfy mice on day 2 following birth. B16 tumor cells were implanted into the scurfy mice at 5 weeks of age, and the mice were
sacrificed 2 weeks later. (B) Competitive population of wild type and CCR7 (2/2) FoxP3+ T cells in tumors. Wild type CD45.1+ CD4+ T cells and CCR7
(2/2) CD45.2+ CD4+ T cells were co-transferred into FoxP3-deficient scurfy mice on day 2 following birth. B16 tumor cells were implanted into the
scurfy mice at 5 weeks of age, and the mice were sacrificed 2 weeks later. (C) Expression of CCR7 and CD62L by wild type FoxP3+ T cells populating
tumors or lymph nodes of scurfy mice. Representative and combined data obtained from 3–4 different experiments are shown. ‘‘*’’ indicates
significant differences between wild type and CCR7 (2/2) FoxP3+ T cells.
doi:10.1371/journal.pone.0030793.g006
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been determined if these FoxP3+ T cells would stay as FoxP3+ T
cells or lose the FoxP3 expression and become FoxP32 non-Tregs.
We formed B16 tumors on the flank of FoxP3-GFP-Cre6RosatdTomato mice. These mice express two fluorescent proteins GFP
and tdTomato under the control of the FoxP3 promoter. Current
FoxP3+ T cells are GFP+ tdTomato+, whereas ex-FoxP3+ T cells
converted back to FoxP32 cells are GFP2 tdTomato+. We found
that the majority of tumor-infiltrating FoxP3+ T cells were GFP+
tdTomato+ cells (Fig. 8A and B). Only ,10% of tumor-infiltrating
FoxP3+ T cells were GFP2 tdTomato+ cells, suggesting that only
,1 out 10 FoxP3+ T cells in tumors lost the FoxP3 expression
since their immigration into tumors or generation.

Decreased expression of CCR7 accompanies
up-regulation of other trafficking receptors on
tumor-infiltrating FoxP3+ T cells

It has been established that FoxP3+ T cells undergo a trafficking
receptor switch following antigen priming in secondary lymphoid
tissues. It is likely that a similar switch could occur for tumorinfiltrating FoxP3+ T cells. We examined expression of CCR8 and
CXCR4, two chemokine receptors associated with migration of
Tregs, by the FoxP3+ T cells in the lymph node and tumors. We
observed that tumor-infiltrating FoxP3+ T cells highly expressed
CCR8, while lymph node-residing FoxP3+ T cells express CCR8
at a relatively lower level. CXCR4, while expressed by FoxP3+ T
cells of both tissues, was better expressed by tumor-infiltrating
FoxP3+ T cells (Fig. 7A). We performed an in vitro chemotaxis
assay with the chemokine ligands for CCR8 and CXCR4 (CCL1
and CXCL12) and observed these chemokines induced more
efficient chemotaxis of tumor-infiltrating FoxP3+ T cells compared
to their counterparts in lymph nodes (Fig. 7B). At the same time,
the responses of the FoxP3+ T cells in tumors to CCR7 ligands
(CCL19 and CCL21) were significantly decreased compared to
their counterparts in lymph nodes. These results indicate the
presence of a trafficking receptor switch from ‘‘CCR7+ CXCR4medium
CCR82’’ to ‘‘CCR72 CXCR4highCCR8+’’ for migration of FoxP3+
T cells from the lymph node into tumors.

Discussion
Tregs, best exemplified by FoxP3+ T cells, have potent
regulatory functions through expression of immune regulatory
factors such as LAP-TGFß1, IL-10, and IL-35 [38–41]. Enrichment of Tregs in many types of tumors is believed to have
significant impacts on anti-tumor immune responses and cancer
patients [42]. Previous studies have indicated that migration of
Tregs into tumors would play major roles in infiltration of Tregs in
tumors [16,24,43–46]. Some groups reported that induced Tregs
are the major cell type in tumors, and tumor-derived TGFß1 is
important for induction of tumor-associated Tregs [27,47,48].
Despite the previous studies, the biological processes that regulate
the enrichment of FoxP3+ T cells in tumors are still unclear. We
performed experiments to provide insights into the biological
processes that contribute to population of FoxP3+ T cells in
tumors. The results indicate that Helios+ FoxP3+ T cells, antigen

Most FoxP3+ T cells in tumors are highly stable and retain
FoxP3 expression

Once migrated into tumors, FoxP3+ T cells are believed to
undergo antigen priming for maintenance or expansion. It has not

Figure 7. Expression of memory T cell trafficking receptors by tumor infiltrating FoxP3+ T cells. (A) Expression of CCR7, CCR8 and CXCR4
by tumor versus PLN-residing FoxP3+ T cells. (B) Chemotaxis of tumor versus PLN-residing FoxP3+ T cells to CCL19 and CCL21 (CCR7 ligands), CCL1
(CCR8), and CXCL12 (CXCR4). Cells from A20 tumor-bearing mice were examined. Representative (A) or combined (B) data obtained from 4–7
different experiments are shown.
doi:10.1371/journal.pone.0030793.g007
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Figure 8. Most tumor-infiltrating FoxP3+ cells retain FoxP3 expression in vivo. FoxP3-GFP-Cre6Rosa-tdTomato mice were implanted with
B16 cells to form tumors. Expression of GFP on tdTomato+ cells was examined by flow cytometry. GFP+ tdTomato+ T cells are current FoxP3+ T cells,
whereas GFP2 tdTomato+ T cells are ex-FoxP3+ T cells. Representative (A) and combined (B) data obtained from 4 different experiments are shown.
doi:10.1371/journal.pone.0030793.g008

cell carcinoma were mostly positive for Helios [57]. These
observations may support the view that most tumor-infiltrating
FoxP3+ T cells are derived originally from the FoxP3+ T cells
generated in the thymus. This information, however, should be
interpreted with caution if Helios expression is further regulated by
non-thymus factors. Indeed, expression of Helios is transiently
detected in activated T cells that are undergoing proliferation [36].
Therefore, high expression of Helios by tumor FoxP3+ T cells
most likely indicates the activation state of the T cells in tumors.
Most tumor-associated FoxP3+ T cells are CD62L2 CCR72.
Antigen-primed CCR7 (2/2) FoxP3+ T cells were more efficient
than antigen primed CCR7 (+/+) FoxP3+ T cells in migration into
tumors. This indicates that loss of CCR7 has a direct impact on
migration of Tregs into tumors. Paradoxically, our results indicate
that primarily naı̈ve antigen-inexperienced CCR7 (2/2) FoxP3+
T cells fail to populate tumors. This is because antigen priming is
required for generation of tumor-infiltrating Tregs in addition to
simple loss of CCR7, which normally occurs during differentiation
of T cells in secondary lymphoid tissues. In this regard, nonantigen primed naı̈ve FoxP3+ T cells are inefficient in migration
into tumors. In addition to CCR7, down- or up-regulation of other
trafficking receptors such as adhesion molecules (e.g. CD62L) and
memory type trafficking receptors should occur for generation of
Tregs that can efficiently migrate into tumors. Certain memory
type trafficking receptors such as CCR4, CXCR4, and CCR5 are
implicated in migration of FoxP3+ T cells into tumors
[16,23,24,58]. Our data indicate that CCR8 and CXCR4 are
up-regulated on tumor-infiltrating FoxP3+ T cells. Loss of CCR7
and CD62L occurs during antigen priming in secondary lymphoid
tissues and is important for migration of T cells to non-lymphoid
tissues. CCR7 and CD62L are the most important trafficking

primed in secondary lymphoid tissues, are the major subset of
Tregs in tumors. Additionally, the results provide insights into the
important roles of antigen priming in draining lymph nodes and
down-regulation of lymphoid tissue homing receptors and
subsequent infiltration of FoxP3+ T cells into tumors. In addition,
our study provides insights into the stability of FoxP3+ T cells intumors.
Prevailing theories to account for the enrichment of Tregs in
tumors are 1) the induction theory [25–28] and 2) the migration
theory [16]. Regarding the ‘‘induction theory,’’ it is believed that
tumors produce certain factors that promote the conversion of
conventional FoxP32 T cells into FoxP3+ regulatory T cells.
Factors that are known for generation of Tregs include cytokines
and tissue factors including TGFb1, retinoic acid, prostaglandin,
progesterone and metabolic/micro-environmental factors [28,49–
56]. Most importantly, induction of FoxP3+ T cells requires TCR
activation or antigen priming, which is required also for
generation of all effector T cells. Because of the variability in
availability of Treg-inducing tissue factors and antigens, tumors
are expected to be extremely heterogeneous in their Treg-inducing
capacity. Our data indicate that induction of Tregs in tumors
would occur at low levels compared to induction in the tumordraining lymph node. This is perhaps because induced Tregs are
mostly generated from naı̈ve T cells which are rare in the tumors
that we examined in this study.
Helios is a member of the Ikaros transcription factor family and
is preferentially expressed by thymus-derived FoxP3+ T cells but
decreased in induced Tregs in mice [35]. Our data indicate that
tumor-infiltrating FoxP3+ T cells are largely positive for Helios
expression. In support of our observation, it has been recently
reported that peripheral blood Tregs in human patients with renal
PLoS ONE | www.plosone.org
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receptors for migration of T cells into secondary lymphoid tissues
such as the tumor-draining lymph node [59]. We observed that
tumor-infiltrating FoxP3+ T cells highly express CCR8 and
CXCR4, chemokine receptors associated respectively with
memory cells and tumors. Therefore, loss of CD62L and CCR7
and up-regulation of certain memory type trafficking receptors are
closely linked to migration of FoxP3+ T cells from secondary
lymphoid tissues into tumors.
In the tumor types where Treg frequencies are linked to
increased tumor growth and decreased patient survival, Treg
depletion would be useful to mount anti-tumor immunity and
enhance patient survival. Our results imply that simple depletion
of the Tregs specifically in the tumors would not be effective as
preformed Tregs can continually immigrate into tumors from the
circulation. Therefore, it would be more effective to comprehensively deplete all Tregs that can migrate into tumors. In addition to
depletion of Tregs, blocking the migration of Tregs into tumors is
a potentially beneficial treatment. Blocking CCR8 and CXCR4
may lead to inhibition of migration of Tregs into tumors. A caveat
is that some non-Treg effector T cells would also express these
receptors [5] and their migration could be affected by the
manipulation at the same time. In this case, anti-tumor immunity
could be negatively affected by blocking of the trafficking
receptors.
It is thought that tumors produce certain tissue factors that
promote the induction and maintenance of Tregs. Our results

underlie the importance of migration and maintenance of Tregs
for their infiltration into tumors. In this regard, most T cells that
were once FoxP3+ T cells retain their expression of FoxP3 in
tumors, suggesting that tumor-infiltrating FoxP3+ T cells are
highly stable in tumors. There are two reasons that make
induction of FoxP3+ T cells in tumors inefficient. First, naı̈ve
FoxP32 cells, which are preferential precursors of FoxP3+ T cells,
would not readily migrate into tumors and therefore are rare in
many types of tumors. Second, conventional memory FoxP32 T
cells, while they can become effector T cells, are relatively
inefficient to become FoxP3+ T cells. Our results, however, do not
rule out the possibility of induction of Tregs in tumors because
Treg induction in tumors is likely to be dependent on the tumor
type and anatomical location of tumors.
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